Advanced search

Search our library

Natural products
Adaptive trial
Phase 1, 2, 3, 4 trials
Clinical Development
Bacterial efflux
Therapeutic index
Minimum inhibitory concentration (MIC)
Maximum tolerated dose (MTD)
Investigational new drug (IND)
Pandrug-resistant (PDR)
Epidemiological cut-off value (ECOFF)
Breakpoint concentration, clinical
Pharmacokinetics-pharmacodynamics (PK/PD)
Lipophilicity
Tissue concentration
Intracellular concentration
Superiority trial
Preclinical development
Plasma protein binding
Plasma concentration
Median effective dose (ED50)
Antiseptic
Toxicity
Therapeutic window
Bacterial target
Target validation
Target product profile (TPP)
Target candidate profile (TCP)
Standard of care (SOC)
Septic shock
Sepsis
Antimicrobial resistance (AMR)
Randomized clinical trial (RCT)
Qualified infectious disease product (QIDP)
Pro-drug
Placebo-controlled trial
Pharmacovigilance
Non-inferiority margin
New drug application (NDA)
New chemical entity (NCE), new molecular entity (NME)
Medicinal chemistry
Median lethal dose (LD50)
Mechanism of action (MoA)
LogD
LogP
Lead compound
Hit-to-lead (HTL), lead generation
Hit identification, hit discovery
Hit confirmation, hit validation
High-throughput screen (HTS)
Extensively drug-resistant (XDR)
ESKAPE
Drug product, medicinal product
Chemistry, manufacturing and controls (CMC)
Cmax
Ames test
Absorption, distribution, metabolism, elimination (ADME)
Bactericidal
Antimicrobial susceptibility testing (AST), resistance testing
Antibiotic, antibacterial and antimicrobial